DiaMedica Therapeutics (DMAC) Operating Expenses (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Operating Expenses for 9 consecutive years, with $10.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 31.11% year-over-year to $10.5 million; the trailing twelve-month figure through Jun 2026 stood at $39.2 million (up 24.71% YoY), and the FY2025 full-year result was $34.4 million, up 28.92% from the prior year.
• Operating Expenses held at $10.5 million in Q2 2026 per DMAC's latest filing, from $10.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $10.5 million in Q2 2026 and bottomed at $3.1 million in Q3 2022.
• Historically, Operating Expenses has averaged $6.5 million across 5 years, with a median of $5.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses retreated 8.43% in 2022, then soared 64.87% in 2023.
• Over 5 years, Operating Expenses stood at $4.0 million in 2022, then soared by 47.19% to $5.8 million in 2023, then surged by 43.96% to $8.4 million in 2024, then advanced by 9.43% to $9.2 million in 2025, then gained by 13.95% to $10.5 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $10.5 million, $10.5 million, and $9.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.